Predictors of treatment duration in patients with metastatic hormone-sensitive prostate cancer (mHSPC) treated with enzalutamide: a post hoc analysis of ARCHES

Andrew J. Armstrong, MD, MS

May 31, 2026; 9:00 AM CDT